Table 3.
Serum supplemented with TNF-α/EGF/EGFR inhibitor, open wound surface area (%) of the original at 48 h
| Serum | Cytokine | Amount of cytokine | Number of wounds | Mean % (SD) | P value |
|---|---|---|---|---|---|
| Healthy (control) | − | − | 8 | 61 (15) | |
| Sepsis (control) | − | − | 8 | 75 (20) | |
| Healthy | TNF-α | 5 ng/ml | 8 | 14 (15) | <0.001 |
| Sepsis | TNF-α | 5 ng/ml | 7 | 44 (19) | 0.009 |
| Healthy | TNF-α | 10 ng/ml | 7 | 13 (15) | <0.001 |
| Sepsis | TNF-α | 10 ng/ml | 5 | 30 (20) | 0.002 |
| Healthy | TNF-α | 50 ng/ml | 6 | 7 (16) | 0.002 |
| Sepsis | TNF-α | 50 ng/ml | 5 | 16 (18) | 0.005 |
| Healthy | EGF | 5 ng/ml | 6 | 0 (0) | 0.001 |
| Sepsis | EGF | 5 ng/ml | 8 | 2 (5) | 0.001 |
| Healthy | EGF | 10 ng/ml | 8 | 9 (17) | 0.001 |
| Sepsis | EGF | 10 ng/ml | 6 | 72 (57) | 0.301 |
| Healthy | EGF | 50 ng/ml | 4 | 51 (59) | 0.768 |
| Sepsis | EGF | 50 ng/ml | 6 | 77 (39) | 0.887 |
| Healthy | EGFr inhibitor | 1 µg/ml | 7 | 84 (24) | 0.037 |
| Sepsis | EGFr inhibitor | 1 µg/ml | 7 | 96 (7) | 0.008 |
| Healthy | EGFr inhibitor | 10 µg/ml | 5 | 95 (11) | 0.001 |
| Sepsis | EGFr inhibitor | 10 µg/ml | 6 | 106 (10) | 0.005 |
| Healthy | EGFr inhibitor | 50 µg/ml | 7 | 95 (4) | 0.001 |
| Sepsis | EGFr inhibitor | 50 µg/ml | 7 | 99 (2) | 0.001 |
Healthy serum samples are compared to healthy control serum and sepsis serum samples to sepsis control serum. Significant P values are in italic